Considering the ongoing evaluation and testing of Ehmt2 inhibitors in preclinical studies in Sickle Cell Anemia, which also affect Beta Globin genes, and combination therapies for pancreatic cancer, our findings warrant careful consideration regarding their potential to attenuate pancreatic defenses against inflammatory stimuli (Yuan et al., 2013; Krivega et al., 2015; Renneville et al., 2015; Pan et al., 2016; Katayama et al., 2020; Urrutia et al., 2020; Takase et al., 2023). This evidence concerns the gene EHMT2 and pancreatic neoplasm.